Literature DB >> 25511624

Circuit life versus bleeding risk: the impact of achieved activated partial thromboplastin time versus achieved filtration fraction.

Clare MacEwen1,2,3, Peter Watkinson1,3, Christopher Winearls2.   

Abstract

Whilst prolonging hemofilter (circuit) life, heparin increases bleeding risk. The impact of achieved activated partial thromboplastin time (APTT) on circuit life and bleeding risk has not been assessed in a modern critically ill cohort. Lowering filtration fraction may be an alternative means of prolonging circuit life, but is often overlooked in critical care. An observational study of 309 consecutive circuits in a general intensive care unit was conducted using a wide target APTT range. Multilevel modeling was used to predict circuit life and bleeding according to achieved APTT and filtration fraction. Independent predictors of circuit failure (i.e. unplanned ending of treatment) included filtration fraction (P<0.001, HR 1.07 per 1% increase), peak APTT (P<0.001, HR 0.8 per 10 s increase or 0.3 APTR increase) and baseline PT (P=0.014, HR 0.91 for every 50% increase). The only significant predictor of bleeding was peak APTT (P=0.017, OR 1.05 per 10 s increase). Every 10 s APTT increase was associated with a 20% reduction in circuit failure, but a 5% increase in hemorrhage. A 3% reduction in filtration fraction was associated with the same improvement in circuit life as a 10 s increase in APTT. Increasing APTT prolongs circuit life but carries a substantial risk of bleeding even in modern practice. Filtration fraction has a large impact on circuit life in the critically ill: a 3% reduction in filtration fraction, e.g. by increasing blood flow or delivering some of the clearance via dialysis, would be expected to reduce circuit failure as much as a 10 s increase in APTT.
© 2014 The Authors. Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis.

Entities:  

Keywords:  Anticoagulation; Circuit life; Filtration fraction; Hemofiltration; Unfractionated heparin

Mesh:

Substances:

Year:  2014        PMID: 25511624     DOI: 10.1111/1744-9987.12253

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  3 in total

1.  Revisiting Filtration Fraction as an Index of the Risk of Hemofilter Clotting in Continuous Venovenous Hemofiltration.

Authors:  Parta Hatamizadeh; Ashita Tolwani; Paul Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2020-05-13       Impact factor: 8.237

2.  Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study.

Authors:  Doug W Gould; James Doidge; M Zia Sadique; Mark Borthwick; Robert Hatch; Fergus J Caskey; Lui Forni; Robert F Lawrence; Clare MacEwen; Marlies Ostermann; Paul R Mouncey; David A Harrison; Kathryn M Rowan; J Duncan Young; Peter J Watkinson
Journal:  Health Technol Assess       Date:  2022-02       Impact factor: 4.014

3.  Development and External Validation of a Model for Predicting Sufficient Filter Lifespan in Anticoagulation-Free Continuous Renal Replacement Therapy Patients.

Authors:  Wei Zhang; Ming Bai; Ling Zhang; Yan Yu; Yangping Li; Lijuan Zhao; Yuan Yue; Yajuan Li; Min Zhang; Ping Fu; Shiren Sun; Xiangmei Chen
Journal:  Blood Purif       Date:  2021-10-21       Impact factor: 3.348

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.